CorMedix Inc
NASDAQ:CRMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CorMedix Inc
Accumulated Depreciation
CorMedix Inc
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CorMedix Inc
NASDAQ:CRMD
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accumulated Depreciation
-$31.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accumulated Depreciation
-$5.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Accumulated Depreciation
-$17.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accumulated Depreciation
-$21.9B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accumulated Depreciation
-$12.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-4%
|
|
CorMedix Inc
Glance View
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
